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Nonalcoholic fatty liver disease (NAFLD) is no longer 
considered to be a normal physiologic condition without any 
clinical significance. It is now widely accepted that nonalcoholic 
steatohepatitis (NASH), a type of fatty liver disease, can 
progress to end-stage liver disease and increase the risk of 
mortality. In addition, NAFLD patients are associated with a 
significantly higher overall mortality as well as liver-related 
mortality compared to the age- and gender-adjusted general 
population.
1,2 Accordingly, several studies have been conducted 
to redefine the normal ranges of liver function tests, especially 
alanine aminotransferase (ALT) levels considering the influence 
of NAFLD on serum ALT level. 
However, there are two different ways to interpret ALT 
levels. Piton et al suggested that these levels should be 
interpreted with respect to the body mass index (BMI) 
considering the positive association between ALT level and 
BMI.
3 However, this concept was questioned by Prati et al
4 
since NAFLD itself is not necessarily a benign liver disease 
without clinical significance. The normal range of ALT 
levels is significantly lower than the conventional cut-off 
levels (41 IU/L for men and 30 U/L for women) if patients 
with risk factors for NAFLD are excluded. This finding was 
also observed in a Korean population in which patients with 
NAFLD were excluded histologically.
5 Another important 
study from Korea also showed a positive association between 
ALT level even within the normal range by conventional 
criteria and liver-related mortality.
6 All these findings suggested 
that the normal range of ALT level (along with those of 
other liver function test factors) should be adjusted. However, 
several points should be considered before applying the 
revised upper limit of normal serum ALT levels.
A study by Oh et al
7 reported that the incidence of 
metabolic syndrome and NAFLD correlates with ALT and 
γ-glutamyltransferase (GGT) levels within the conventional 
reference ranges. About half of the subjects with ALT levels 
in the upper fourth quartile of the conventional normal range 
had fatty liver disease that appeared on ultrasonography. 
This finding strongly suggests that adjustment of the normal 
range for ALT level can increase the detection rates of 
patients with NAFLD. However, the study population consisted 
of individuals who underwent health check-ups voluntarily, 
and therefore could have introduced selection biases. 
Another unanswered question is what proportion of patients 
with NAFLD actually has histologically-diagnosed NASH. 
It is generally accepted that liver-related mortality does not 
increase in patients with simple steatosis. We do not and 
probably cannot conclusively determine if this is actually 
the case in near future since liver biopsy is still the only test 
that can differentiate NASH from simple steatosis. The 
incidence of NASH was reported to be 2.2% among Korean 
living liver donors among whom the overall incidence of 
NAFLD was 51.4%.
8 Therefore, the prevalence of NASH 
among individuals with NAFLD is estimated to be 4.3%. 
Since this study included patients with ALT level elevated 
up to 120 IU/L, the proportion of NASH cases may be different 
(probably lower) among fatty liver disease patients with normal 
ALT level as defined by conventional criteria. Therefore, 
further studies are needed to investigate whether the adjustment 10  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
of the normal range of ALT levels is cost-effective or can 
reduce long-term liver-related mortality. 
Secondly, ALT or GGT (and other liver function tests) is 
primarily used for screening for liver disease and to determine 
the appropriate treatment for patients with liver diseases. 
Several follow-up studies have demonstrated that elevated 
ALT or GGT level is associated with increased overall 
mortality including death from cardiovascular disease or 
cancers and/or liver-related mortality.
9,10 However, even though 
serum ALT and GGP levels may predict the development of 
metabolic syndrome or increased mortality, adoption of these 
tests to screen for metabolic syndrome or other diseases is 
quite a different story. For practical reasons, serum ALT or 
GGT levels are never used as an isolated test to screen for 
liver disease or other diseases in Korea. For example, the 
tests for routine health check-ups sponsored by the National 
Health Insurance Cooperation in Korea include height, 
weight, BMI, blood pressure, fasting blood glucose, total 
cholesterol, aspartate aminotransferase, and ALT and GGT 
levels. In addition, many other programs also include tests 
for serum HBsAg or anti-HCV antibodies. Although serum 
ALT or GGT level within the reference limits can predict the 
development of metabolic syndrome or future mortality 
rates, other parameters including BMI, blood pressure, fasting 
blood glucose levels, and total cholesterol levels, or com-
binations of these factors are probably more informative. 
Furthermore, in the study by Oh et al,
7 serum ALT or GGT 
level was used to predict the presence of pre-existing metabolic 
syndrome, but their usefulness in predicting the development 
of metabolic syndrome or mortality is unknown. Therefore, 
it is still unclear whether the use of serum ALT or GGT 
levels within the upper fourth quartile of the conventional 
normal range is in fact helpful for detecting metabolic 
syndrome or predicting mortality in ordinary clinical practice. 
Thirdly, it is still unknown whether the increase in 
liver-related deaths in Korean people with slightly higher 
aminotransferase activity that still within the normal range 
can be attributed to NAFLD or other liver diseases including 
autoimmune hepatitis or Wilson’s disease.
6 In the study by 
Kim et al,
6 serum HBsAg and/or anti-HCV antibody levels 
were not tested, and the presence of underlying liver 
cirrhosis was excluded only by a self-report questionnaire. 
History of alcohol abuse was also obtained only by the 
self-report questionnaire. Therefore, it is still unknown whether 
the increased number of liver-related deaths was caused by 
unreported chronic hepatitis B virus (HBV) infection and/or 
alcohol- related cirrhosis, or by other liver diseases including 
NAFLD, cryptogenic liver disease, autoimmune hepatitis, or 
Wilson’s disease. Given that Korea is an area with endemic 
chronic HBV infection and high rates of alcohol abuse, the 
former scenario is more likely. Therefore, the clinical benefit 
from improved detection of NAFLD by a revised normal 
range of ALT or GGT is largely unknown, and should be 
addressed by future studies.
In conclusion, many studies have demonstrated that the 
conventional normal range of ALT level or those of other 
liver function test factors should be adjusted to account for 
the influence of NAFLD. In addition, emerging data have 
suggested that serum ALT activity may serve not only as a 
marker of liver diseases but also as an indicator of metabolic 
syndrome or general health. However, despite its potential 
role as an indicator of NAFLD or metabolic syndrome even 
within the conventional reference ranges, it is still unknown 
whether the adjustment of the normal cut-off level of ALT 
can help reduce liver-related or overall mortality rates with 
acceptable cost-effectiveness. Future studies are needed to 
address this issue.
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